URB2

Summary

URB2 (URB2 ribosome biogenesis homolog, HGNC:28967) is a protein-coding gene on chromosome 1q42.13, encoding Unhealthy ribosome biogenesis protein 2 homolog (Q14146). Essential for hematopietic stem cell development through the regulation of p53/TP53 pathway. It is a selective cancer dependency (DepMap: 88.9% of cell lines).

Predicted to be involved in regulation of signal transduction by p53 class mediator and ribosome biogenesis. Located in aggresome; midbody; and nucleolus.

Source: NCBI Gene 9816 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 247 total — 1 pathogenic
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 88.9% of screened cell lines
• MANE Select transcript: NM_014777

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28967
Approved symbol	URB2
Name	URB2 ribosome biogenesis homolog
Location	1q42.13
Locus type	gene with protein product
Status	Approved
Aliases	NPA2, NET10
Ensembl gene	ENSG00000135763
Ensembl biotype	protein_coding
OMIM	619372
Entrez	9816

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000258243, ENST00000434387, ENST00000869045, ENST00000922771, ENST00000922772, ENST00000922773, ENST00000944234

RefSeq mRNA: 2 — MANE Select: NM_014777 NM_001314021, NM_014777

CCDS: CCDS31052

Canonical transcript exons

ENST00000258243 — 10 exons

Exon	Start	End
ENSE00000921362	229634917	229638247
ENSE00000921363	229643533	229643693
ENSE00000921364	229645859	229645969
ENSE00000921365	229647510	229647752
ENSE00000921366	229651235	229651322
ENSE00000921367	229654249	229654388
ENSE00001120505	229632269	229632445
ENSE00001120516	229626247	229626356
ENSE00001175529	229659100	229660200
ENSE00001175534	229627621	229627759

Expression profiles

Bgee: expression breadth ubiquitous, 197 present calls, max score 82.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.4642 / max 50.0734, expressed in 1653 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
9010	6.3445	1651
9011	0.1197	38

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.46	gold quality
gastrocnemius	UBERON:0001388	78.15	gold quality
muscle of leg	UBERON:0001383	77.08	gold quality
ventricular zone	UBERON:0003053	76.82	gold quality
stromal cell of endometrium	CL:0002255	75.41	gold quality
islet of Langerhans	UBERON:0000006	75.22	gold quality
ganglionic eminence	UBERON:0004023	75.09	gold quality
hindlimb stylopod muscle	UBERON:0004252	74.52	gold quality
tibia	UBERON:0000979	73.86	gold quality
cortical plate	UBERON:0005343	73.76	gold quality
embryo	UBERON:0000922	73.55	gold quality
skeletal muscle organ	UBERON:0014892	73.16	gold quality
muscle organ	UBERON:0001630	73.15	gold quality
tongue squamous epithelium	UBERON:0006919	72.77	gold quality
cartilage tissue	UBERON:0002418	72.65	silver quality
left uterine tube	UBERON:0001303	72.57	gold quality
hair follicle	UBERON:0002073	72.39	gold quality
adrenal tissue	UBERON:0018303	72.08	gold quality
pancreas	UBERON:0001264	71.88	gold quality
right adrenal gland cortex	UBERON:0035827	71.57	gold quality
right adrenal gland	UBERON:0001233	71.54	gold quality
granulocyte	CL:0000094	71.49	gold quality
esophagus mucosa	UBERON:0002469	71.38	gold quality
squamous epithelium	UBERON:0006914	71.36	silver quality
left adrenal gland	UBERON:0001234	71.30	gold quality
mucosa of transverse colon	UBERON:0004991	71.29	gold quality
peritoneum	UBERON:0002358	71.28	gold quality
omental fat pad	UBERON:0010414	71.28	gold quality
leukocyte	CL:0000738	71.19	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.29

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

43 targeting URB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-1825	99.72	68.11	1089
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-186-3P	99.51	66.24	1685
HSA-MIR-217-5P	99.49	69.93	1419
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-4480	99.42	66.02	735
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-6505-3P	99.34	67.39	1071
HSA-MIR-10522-5P	99.26	68.50	2087
HSA-MIR-6807-3P	99.15	69.23	1275
HSA-MIR-4656	98.79	66.22	1306
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-4635	98.74	67.63	1339
HSA-MIR-655-5P	98.74	65.93	888
HSA-MIR-6830-3P	98.62	68.07	1760

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 88.9% of screened cell lines.

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	urb2	ENSDARG00000003217
mus_musculus	Urb2	ENSMUSG00000031976
rattus_norvegicus	Urb2	ENSRNOG00000026853

Protein

Protein identifiers

Unhealthy ribosome biogenesis protein 2 homolog — Q14146 (reviewed: Q14146)

All UniProt accessions (2): Q14146, Q5VYD0

UniProt curated annotations — full annotation on UniProt →

Function. Essential for hematopietic stem cell development through the regulation of p53/TP53 pathway.

Subcellular location. Nucleus. Nucleolus.

RefSeq proteins (2): NP_001300950, NP_055592* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR018849	Urb2/Npa2_C	Domain
IPR052609	Ribosome_Biogenesis_Reg	Family

Pfam: PF10441

UniProt features (3 total): sequence variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14146-F1	82.66	0.28

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 146 (showing top): ELVIDGE_HYPOXIA_DN, GOBP_RIBOSOME_BIOGENESIS, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, PUJANA_CHEK2_PCC_NETWORK, WEI_MYCN_TARGETS_WITH_E_BOX, HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN, LIAO_METASTASIS, GOBP_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_REGULATION_OF_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, GOCC_MIDBODY, GOCC_NUCLEOLUS, ELVIDGE_HIF1A_TARGETS_UP

GO Biological Process (2): ribosome biogenesis (GO:0042254), regulation of signal transduction by p53 class mediator (GO:1901796)

GO Molecular Function (0):

GO Cellular Component (4): nucleolus (GO:0005730), aggresome (GO:0016235), midbody (GO:0030496), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ribonucleoprotein complex biogenesis	1
signal transduction by p53 class mediator	1
regulation of intracellular signal transduction	1
nuclear lumen	1
intracellular membraneless organelle	1
inclusion body	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1505 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
URB2	URB1	O60287	860
URB2	TAF1B	Q53T94	581
URB2	BKGD	Q9H0W9	480
URB2	FAM89B	Q8N5H3	478
URB2	UNC119B	A6NIH7	450
URB2	ZNF567	Q8N184	430
URB2	SYCE1L	A8MT33	426
URB2	FAM194C	Q8ND61	400
URB2	ZNF775	Q96BV0	400
URB2	UTP15	Q8TED0	396
URB2	SCCPDH	Q8NBX0	377
URB2	CCDC102B	Q68D86	375
URB2	WDR43	Q15061	362
URB2	PRPSAP1	Q14558	361
URB2	DENND2C	Q68D51	358

IntAct

111 interactions, top by confidence:

A	B	Type	Score
VSIG1	TTI1	psi-mi:“MI:0914”(association)	0.640
FGF3	GTPBP10	psi-mi:“MI:0914”(association)	0.530
MECP2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
ZNF512	ZNF724	psi-mi:“MI:0914”(association)	0.530
RBM34	NVL	psi-mi:“MI:0914”(association)	0.530
RRP8	NVL	psi-mi:“MI:0914”(association)	0.530
MACROH2A2	PPM1G	psi-mi:“MI:0914”(association)	0.530
SCN3B	ABCC5	psi-mi:“MI:0914”(association)	0.530
RPL18A	RRP8	psi-mi:“MI:0914”(association)	0.530
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
CCDC59	GAPDHS	psi-mi:“MI:0914”(association)	0.530
VSIG1	TNPO2	psi-mi:“MI:0914”(association)	0.530
RBM4	NVL	psi-mi:“MI:0914”(association)	0.530
SRPK2	RRP9	psi-mi:“MI:0914”(association)	0.530
ILVBL	SLC33A1	psi-mi:“MI:0914”(association)	0.530
APLNR	SLC33A1	psi-mi:“MI:0914”(association)	0.530
ABT1	ZNF316	psi-mi:“MI:0914”(association)	0.530
URB2	RPL13A	psi-mi:“MI:0914”(association)	0.530
DGCR2	HOXD13	psi-mi:“MI:0914”(association)	0.530
RPL13A	NVL	psi-mi:“MI:0914”(association)	0.530
URB2	PLEC	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (138): URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS), URB2 (Affinity Capture-MS)

ESM2 similar proteins: A0JM49, A2AKG8, B0V0U5, B1AUR6, C5J7W8, E1BGH8, E1C231, E1C2Z0, E7FGT5, E7FH61, E9Q3L2, F6S215, O08662, O60287, O94822, P42356, P57678, P78527, P97313, Q13315, Q13535, Q14146, Q1RLU1, Q2TAW0, Q3TQQ9, Q3URQ0, Q571H0, Q5RDK1, Q5VW36, Q5WNI9, Q5XI94, Q5ZM41, Q62388, Q6A009, Q6DFV1, Q6PQD5, Q6ZRQ5, Q7SY48, Q86XI2, Q8BKX6

Diamond homologs: B0V0U5, Q14146

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 131 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	10	16.1×	4e-08
Viral mRNA Translation	10	16.1×	4e-08
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	10	15.9×	4e-08
Selenocysteine synthesis	10	15.2×	4e-08
Eukaryotic Translation Termination	10	15.2×	4e-08
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	10	14.9×	4e-08
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	10	14.9×	4e-08
rRNA modification in the nucleus and cytosol	6	14.2×	7e-05

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of viral genome replication	5	16.0×	2e-03
cytoplasmic translation	10	15.8×	3e-07
negative regulation of translation	8	13.4×	3e-05
rRNA processing	10	12.1×	2e-06
translation	13	11.4×	8e-08

Disease & clinical

Clinical variants and AI predictions

ClinVar

247 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	203
Likely benign	24
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3391841	GRCh37/hg19 1q42.13-43(chr1:228803269-243112182)x3	Pathogenic

SpliceAI

2100 predictions. Top by Δscore:

Variant	Effect	Δscore
1:229627760:G:GG	donor_gain	1.0000
1:229634908:A:AG	acceptor_gain	1.0000
1:229634910:T:G	acceptor_gain	1.0000
1:229645858:GGCT:G	acceptor_gain	1.0000
1:229647506:TTAGC:T	acceptor_loss	1.0000
1:229647507:TAGCT:T	acceptor_loss	1.0000
1:229647508:A:AG	acceptor_gain	1.0000
1:229647509:G:GC	acceptor_gain	1.0000
1:229647509:GC:G	acceptor_gain	1.0000
1:229647509:GCT:G	acceptor_gain	1.0000
1:229647509:GCTC:G	acceptor_gain	1.0000
1:229647509:GCTCT:G	acceptor_gain	1.0000
1:229647749:TAAG:T	donor_loss	1.0000
1:229647750:AAG:A	donor_loss	1.0000
1:229647751:AGG:A	donor_loss	1.0000
1:229647752:GGTGA:G	donor_loss	1.0000
1:229647754:T:G	donor_loss	1.0000
1:229654361:GGCCC:G	donor_gain	1.0000
1:229659098:A:AG	acceptor_gain	1.0000
1:229659098:AG:A	acceptor_gain	1.0000
1:229659098:AGGT:A	acceptor_gain	1.0000
1:229659099:G:C	acceptor_loss	1.0000
1:229659099:G:GT	acceptor_gain	1.0000
1:229659099:GG:G	acceptor_gain	1.0000
1:229659099:GGT:G	acceptor_gain	1.0000
1:229659099:GGTG:G	acceptor_gain	1.0000
1:229659099:GGTGA:G	acceptor_gain	1.0000
1:229626352:CCGAG:C	donor_loss	0.9900
1:229626353:CGAGG:C	donor_loss	0.9900
1:229627615:TTTTA:T	acceptor_loss	0.9900

AlphaMissense

9895 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:229627719:C:A	A29D	0.993
1:229632353:T:A	W71R	0.993
1:229632353:T:C	W71R	0.993
1:229627721:T:A	W30R	0.990
1:229627721:T:C	W30R	0.990
1:229635835:T:A	W408R	0.990
1:229635835:T:C	W408R	0.990
1:229635916:T:A	W435R	0.990
1:229635916:T:C	W435R	0.990
1:229635844:T:C	C411R	0.989
1:229632281:T:A	W47R	0.988
1:229632281:T:C	W47R	0.988
1:229627710:C:A	A26D	0.987
1:229627715:T:C	F28L	0.986
1:229627717:T:A	F28L	0.986
1:229627717:T:G	F28L	0.986
1:229627753:A:C	K40N	0.986
1:229627753:A:T	K40N	0.986
1:229635586:T:C	F325L	0.983
1:229635588:C:A	F325L	0.983
1:229635588:C:G	F325L	0.983
1:229635838:T:C	F409L	0.983
1:229635840:C:A	F409L	0.983
1:229635840:C:G	F409L	0.983
1:229636240:A:C	S543R	0.983
1:229636242:C:A	S543R	0.983
1:229636242:C:G	S543R	0.983
1:229632273:T:C	L44S	0.981
1:229635846:T:G	C411W	0.980
1:229659139:G:C	G1473R	0.980

dbSNP variants (sampled 300 via entrez): RS1000061113 (1:229633470 A>T), RS1000225365 (1:229652031 A>T), RS1000281800 (1:229649180 T>C), RS1000308866 (1:229632561 G>A,T), RS1000353081 (1:229638868 G>A), RS1000438663 (1:229649480 C>A), RS1000470818 (1:229655757 A>C), RS1000657933 (1:229656961 T>G), RS1000721092 (1:229649351 A>T), RS1000727300 (1:229655526 G>A), RS1000774013 (1:229643084 G>A,T), RS1000774790 (1:229650739 A>T), RS1000870751 (1:229643328 A>G), RS1000922957 (1:229656537 A>C,G), RS1000986022 (1:229649159 C>A,T)

Disease associations

OMIM: gene MIM:619372 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), epilepsy (MONDO:0005027)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001980_3	Circulating myeloperoxidase levels (plasma)	1.000000e-06
GCST002345_4	Response to cytadine analogues (cytosine arabinoside)	4.000000e-07
GCST007857_6	Fasting blood insulin adjusted for BMI	3.000000e-07
GCST012033_5	Sleep (1/3-day periodicity)	2.000000e-11
GCST90002390_341	Mean corpuscular hemoglobin	3.000000e-15
GCST90002392_257	Mean corpuscular volume	7.000000e-20
GCST90002396_167	Mean reticulocyte volume	7.000000e-21
GCST90002397_755	Mean spheric corpuscular volume	5.000000e-25

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005243	myeloperoxidase measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0010701	mean reticulocyte volume

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D004827	Epilepsy	C10.228.140.490
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067278 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.67	Kd	2118	nM	CHEMBL5653589
5.67	ED50	2118	nM	CHEMBL5653589
5.54	Kd	2878	nM	CHEMBL3752910
5.54	ED50	2878	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149738: Binding affinity to human URB2 incubated for 45 mins by Kinobead based pull down assay	kd	2.1180	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149738: Binding affinity to human URB2 incubated for 45 mins by Kinobead based pull down assay	kd	2.8775	uM

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	increases expression	2
Formaldehyde	decreases expression	2
Nickel	increases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	increases expression, increases methylation	2
Cadmium Chloride	decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
afuresertib	decreases expression	1
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
trichostatin A	affects expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
zinc chromate	increases abundance, decreases expression	1
chromium hexavalent ion	increases abundance, decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Calcitriol	decreases expression, affects cotreatment	1
Cisplatin	affects cotreatment, decreases expression	1
Dimethyl Sulfoxide	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Flame Retardants	increases expression	1
Hydrogen Peroxide	affects expression	1
Methyl Methanesulfonate	decreases expression	1
Oxygen	decreases expression	1
Potassium Dichromate	decreases expression	1
Quercetin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652780	Binding	Binding affinity to human URB2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer